Biomedical Updates


N-Acetylcarnosine Prevents and Reverses Cataracts

According to the latest estimates of the World Health Organization, about 284 million people are visually impaired worldwide: 39 million are blind and 245 have low vision.

In a new report, HPLC analysis was used to search the pathways of ocular metabolic activities for a 1% N-acetylcarnosine eye drop solution and the bioactivation of this molecule for the promotion of transcorneal uptake of L-carnosine in the aqueous humor.1 When a meta-analysis of phase 2 of a randomized double-blind placebo-controlled clinical trial data was conducted, the intraocularly absorbed L-carnosine demonstrated a number of pharmacological mechanisms for the prevention and reversal of cataracts.

The systemic absorption of L-carnosine results in hypothalamic activation that regulates neuronal functions such as the promotion of sensory input in the primary vision perceptual pathway. The discovery of naturally-occurring carnosine derivatives such as N-acetylcarnosine have been found to be an effective treatment for sight-threatening eye disorders.

Reference

  1. Babizhayev MA, Khoroshilova-Maslova IP, Kasus-Jacobi A. Novel intraocular and systemic absorption drug delivery and efficacy of N-acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care. Fundam Clin Pharmacol 2011 Jul 27. doi: 10.1111/j.1472-8206.2011.00963.x. [Epub ahead of print]

Featured Product

Ingredients in this Article

FREE Subscription

  • You're just getting started! We have published thousands of scientific health articles. Stay updated and maintain your health.

    It's free to your e-mail inbox and you can unsubscribe at any time.
    Loading Indicator